OPL 6.25% 1.7¢ opyl limited

Ann: Opyl - Business Update & Appendix 4C, page-10

  1. 130 Posts.
    lightbulb Created with Sketch. 12
    Patient recruitment is a significant problem in biopharma. It’s one of the major reasons why trials are delayed. This co can really contribute in solving this problem.

    they have 1.13mill in funding (loan facility + cash). Net spend this quarter was high, should be a profitable quarter going forward potentially with the previous + upcoming contracts they are going to sign
 
watchlist Created with Sketch. Add OPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.